Monopar a new overweight at Piper Sandler on rare disease asset
Source: SeekingAlpha
2025-03-19 10:27:11 ET
More on Monopar Therapeutics
- Monopar Therapeutics: Strong Data, But There Are Risks
- Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
- Monopar Therapeutics announces pricing of $40M public offering of common stock
- Seeking Alpha’s Quant Rating on Monopar Therapeutics
- Historical earnings data for Monopar Therapeutics
Read the full article on Seeking Alpha
For further details see:
Monopar a new overweight at Piper Sandler on rare disease asset
Monopar Therapeutics Inc.
NASDAQ: MNPR
MNPR Trading
5.23% G/L:
$60 Last:
235,718 Volume:
$58.57 Open:
MNPR Latest News
March 02, 2026 08:00:00 am
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
November 13, 2025 08:00:00 am
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
MNPR Stock Data
$384,114,928
4,169,932
0.03%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmette
